Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Structural determinants of diphenethylamines for interaction with the κ opioid receptor: Synthesis, pharmacology and molecular modeling studies.

Guerrieri E, Bermudez M, Wolber G, Berzetei-Gurske IP, Schmidhammer H, Spetea M.

Bioorg Med Chem Lett. 2016 Oct 1;26(19):4769-4774. doi: 10.1016/j.bmcl.2016.08.031. Epub 2016 Aug 12.

PMID:
27567368
2.

Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opioid receptor agonist.

Spetea M, Berzetei-Gurske IP, Guerrieri E, Schmidhammer H.

J Med Chem. 2012 Nov 26;55(22):10302-6. doi: 10.1021/jm301258w. Epub 2012 Nov 7.

PMID:
23134120
3.

Synthesis and pharmacological activities of 6-glycine substituted 14-phenylpropoxymorphinans, a novel class of opioids with high opioid receptor affinities and antinociceptive potencies.

Spetea M, Windisch P, Guo Y, Bileviciute-Ljungar I, Schütz J, Asim MF, Berzetei-Gurske IP, Riba P, Kiraly K, Fürst S, Al-Khrasani M, Schmidhammer H.

J Med Chem. 2011 Feb 24;54(4):980-8. doi: 10.1021/jm101211p. Epub 2011 Jan 14.

4.

Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime.

Spetea M, Schüllner F, Moisa RC, Berzetei-Gurske IP, Schraml B, Dörfler C, Aceto MD, Harris LS, Coop A, Schmidhammer H.

J Med Chem. 2004 Jun 3;47(12):3242-7.

PMID:
15163203
5.

Binding, pharmacological and immunological profiles of the delta-selective opioid receptor antagonist HS 378.

Spetea M, Harris HE, Berzetei-Gurske IP, Klareskog L, Schmidhammer H.

Life Sci. 2001 Aug 31;69(15):1775-82.

PMID:
11665839
6.

Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.

Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz RW, Haggart D, O'Brien A, White A, Kennedy JM, Craymer K, Farrington L, Auh JS.

NIDA Res Monogr. 1998 Mar;178:440-66. No abstract available.

PMID:
9686407
7.

Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1.

Dooley CT, Spaeth CG, Berzetei-Gurske IP, Craymer K, Adapa ID, Brandt SR, Houghten RA, Toll L.

J Pharmacol Exp Ther. 1997 Nov;283(2):735-41.

PMID:
9353393
8.

A guinea pig ileum preparation devoid of functional kappa receptors: a new in vitro pharmacologic assay for mu-opioid ligands.

Schwartz RW, Chang AC, Portoghese PS, Berzetei-Gurske IP.

Life Sci. 1997;60(15):PL235-9.

PMID:
9096250
9.

Determination of activity for nociceptin in the mouse vas deferens.

Berzetei-Gurske IP, Schwartz RW, Toll L.

Eur J Pharmacol. 1996 Apr 29;302(1-3):R1-2.

PMID:
8791013
10.

The in vitro pharmacological characterization of naloxone benzoylhydrazone.

Berzetei-Gurske IP, White A, Polgar W, DeCosta BR, Pasternak GW, Toll L.

Eur J Pharmacol. 1995 Apr 24;277(2-3):257-63.

PMID:
7493617
11.

Comparison of kappa 2-opioid receptors in guinea pig brain and guinea pig ileum membranes.

Webster JL, Polgar WE, Brandt SR, Berzetei-Gurske IP, Toll L.

Eur J Pharmacol. 1993 Feb 9;231(2):251-8.

PMID:
8095898
12.

The mu-opioid activity of kappa-opioid receptor agonist compounds in the guinea pig ileum.

Berzetei-Gurske IP, Toll L.

Eur J Pharmacol. 1992 Mar 3;212(2-3):283-6.

PMID:
1318215

Supplemental Content

Loading ...
Support Center